Archives
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Acifran’s Structural Basis and Selectivity in Lipid Regulati
2026-05-13
Discover how Acifran, a selective HM74A/GPR109A and GPR109B agonist, reveals the structural determinants of lipid metabolism regulation. This in-depth analysis unpacks recent cryo-EM insights and guides advanced assay design for metabolic disorder research.
-
EdU Imaging Kits (Cy3): Reliable S-Phase Detection for Lab S
2026-05-13
This article offers a scenario-driven, evidence-based exploration of EdU Imaging Kits (Cy3) (SKU K1075) for reproducible S-phase DNA synthesis measurement. Addressing common laboratory challenges, we demonstrate how APExBIO's kit delivers superior sensitivity, workflow safety, and data integrity in cell proliferation, cytotoxicity, and genotoxicity assays. Practical advice is provided for experimental design, protocol optimization, and vendor selection.
-
GANT61 as a Selective GLI Inhibitor: Protocols and Pitfalls
2026-05-12
GANT61, a potent GLI inhibitor from APExBIO, has transformed cancer research by enabling precise Hedgehog pathway modulation and tumor growth suppression. This article delivers stepwise workflows, advanced applications, and troubleshooting strategies for maximizing experimental success with GANT61 in translational models.
-
Anlotinib Hydrochloride Suppresses Angiogenesis via VEGFR2,
2026-05-12
This study demonstrates that anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, potently inhibits angiogenesis by blocking VEGFR2, PDGFRβ, and FGFR1 signaling pathways. The findings offer mechanistic clarity and robust evidence for anlotinib’s superior anti-angiogenic activity compared to established clinical TKIs, providing a valuable resource for cancer biology and translational research.
-
Niclosamide in Cancer Research: Workflow Optimization & Trou
2026-05-11
Niclosamide (5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide) is a potent STAT3 signaling pathway inhibitor, enabling precise cell cycle arrest and apoptosis studies. This article delivers actionable protocols, advanced troubleshooting, and key insights from recent high-impact glioma research to empower your STAT3-targeted experimental workflows.
-
Scutellarin Restores Endothelial Function via Cathepsin D Up
2026-05-11
This study demonstrates that scutellarin mitigates ischemia/reperfusion-induced endothelial dysfunction by upregulating cathepsin D, thereby restoring autophagy-lysosomal function. The findings highlight a mechanistically novel pathway for vascular protection and provide key methodological advances for dissecting lysosomal-autophagic regulation in cardiovascular injury.
-
GKT137831: Redefining Dual Nox1/Nox4 Inhibition for Advanced
2026-05-10
Explore the unique dual NADPH oxidase Nox1/Nox4 inhibitor GKT137831, its profound mechanistic impact on oxidative stress, and how recent insights into membrane lipid remodeling reshape assay design. This article delivers advanced guidance for translational researchers seeking deeper understanding.
-
Olaparib (AZD2281): Mechanism-Driven Strategy for Translatio
2026-05-09
This article synthesizes mechanistic insights and translational guidance for researchers using Olaparib (AZD2281, Ku-0059436), highlighting its role in exploiting DNA repair vulnerabilities in cancer. We bridge rigorous experimental evidence, such as gene expression profiling in mesothelioma, with practical workflow recommendations and strategic outlooks. The discussion expands beyond protocol checklists—demonstrating how APExBIO’s Olaparib enables next-generation DNA damage response assays, tumor radiosensitization studies, and precision BRCA-associated cancer research.
-
(-)-Blebbistatin: Selective Non-Muscle Myosin II Inhibitor I
2026-05-09
(-)-Blebbistatin is a potent and selective non-muscle myosin II inhibitor used to dissect actin-myosin dynamics in cell biology. Its reversibility and specificity enable controlled studies on cell adhesion, migration, and contractility. This article delivers evidence-based parameters and addresses common misconceptions for robust cytoskeletal research.
-
Cardiogreen (Indocyanine Green): Mechanism, Validation, and
2026-05-08
Explore how Cardiogreen (Indocyanine Green) bridges advanced vascular diagnostics and next-generation photodynamic therapy, empowering translational researchers to design protocols with mechanistic clarity and clinical foresight.
-
Direct Measurement of Red Blood Cell Cytoplasmic Membrane Ri
2026-05-07
This study provides the first isolated measurement of the bending modulus of the red blood cell cytoplasmic membrane, using advanced scattering techniques and molecular dynamics simulations. The findings resolve longstanding discrepancies in reported membrane rigidity and inform experimental strategies for modeling blood biomechanics and perioperative blood management.
-
Alternative Splicing of AGL18-1 Regulates Flowering in Brass
2026-05-07
This study uncovers how alternative splicing of the AGL18-1 gene in Brassica juncea generates two functionally distinct protein isoforms, each with opposing effects on flowering time. The findings provide mechanistic insights into photoperiod-induced flowering regulation, with potential implications for crop quality and yield.
-
Dual-Action Kinase Inhibitors Modulate p38α MAPK Dephosphory
2026-05-06
This study uncovers a mechanism by which certain kinase inhibitors not only block kinase activity but also accelerate dephosphorylation of p38α MAP kinase by stabilizing an activation loop conformation accessible to phosphatases. These findings introduce a new strategy for enhancing the specificity and potency of kinase-targeted therapies and have practical implications for the design of next-generation kinase inhibitors.
-
Photothermal/CD47 Blockade Synergy in OSCC: ECM Remodeling a
2026-05-06
This study demonstrates that combining photothermal therapy with CD47 blockade significantly enhances anti-tumor macrophage activity in oral squamous cell carcinoma (OSCC). The dual approach works by inducing calreticulin exposure and remodeling the tumor extracellular matrix, thereby overcoming key barriers to macrophage infiltration and tumor clearance.
-
Bending Rigidity of Red Blood Cell Membranes: New Insights
2026-05-05
This study provides a rigorous quantification of the bending rigidity (κ) of the red blood cell cytoplasmic membrane, distinguishing its mechanical properties from those of the underlying spectrin network. The findings clarify longstanding discrepancies in reported κ values, with implications for understanding red blood cell deformability and related physiological processes.